1. SGLT-2 抑制剂能有效平稳降低血糖 英国前瞻性糖尿病研究(UK Prospective Diabetes Study ,UKPDS)显示糖尿病患者糖化血红蛋白每降低 1%,心肌梗死发生减少 14%[5]。同时,另一项前瞻性研究显示发生低血糖的 2 型糖尿病患者的心血管事件风险则增加 2.09 倍[6]。SGLT-2 抑制剂能有效平稳降低血糖[7-10],一项由...
This study aimed to evaluate the relative association between sodium-glucose cotransporter-2 inhibitors (SGLT2i) and glucagon-like peptide-1 receptor agonists (GLP-1Ra) with the incidence of gout in patients with type 2 diabetes (T2D) using real-world data. We conducted a cohort study using ...
SGLT2 is not expressed on the heart [78], yet there is strong pre-clinical evidence that SGLT2-inhibitors influence Ca2+handling by modulating intracytoplasmic Na+in the cardiomyocyte. This is supported by evidence that empagliflozin improves SERCA2a efficiency [79] and reduces RyR2-dependent Ca2+...
Sodium‐glucose cotransporter‐2 (SGLT2) inhibitors are routinely used in the management of human type 2 diabetes and have been shown to effectively mitigate hyperglycemia and reduce the risks of cardiovascular and renal compromise. Two SGLT2 inhibitors, namely bexagliflozin and velagliflozin, were ...
第二型糖尿病新治疗药物-选择性SGLT2抑制剂-cgmhorgtw.PDF, 總編 :鄧新棠 主編 :李炳鈺 發行所 :林口、高雄、基隆 、台北、 桃園 、雲林、嘉義 ‧長庚紀念醫院 藥劑部 一百零二年十二月十五日出版 第二型糖尿病新治療藥物 選擇性- SGLT2 抑制劑 甘財源
Diabetologia (2024) 67:1817–1827 https://doi.org/10.1007/s00125-024-06190-9 ARTICLE Safety and effectiveness of SGLT2 inhibitors in a UK population with type 2 diabetes and aged over 70 years: an instrumental variable approach Laura M. Güdemann1 · Katie G...
(g) cell proliferation assay for canagliflozin compared to other two OxPhos complex-I inhibitors, and IACS-010759. Ordinary one-way ANOVA with the post hoc Bonferroni’s multiple comparisons test was performed, to determine if there were significant changes between the treatment and control groups....
Perioperative and periprocedural management of GLP-1 receptor-based agonists and SGLT2 inhibitors: narrative review and the STOP-GAP and STOP DKA-2 algorithms Ronald M. Goldenberg, Jeremy D. Gilbert, Robyn L. Houlden, Tayyab S. Khan, Sapna Makhija, C. David Mazer, show all Pages ...
SGLT2 inhibitors are a new class of anti-diabetic agent and human studies in type 1 and 2 diabetes have demonstrated efficacy in blood glucose lowering and acute hemodynamic changes in kidney function9,44. Long-term clinical studies on the incidence of microvascular complications, such as diabetic...
Sodium-glucose cotransporter 2 inhibitors (SGLT2i) are antidiabetic medications which act by inhibiting the reabsorption of sodium and glucose in the proximal tubules of the kidney [13]. Commonly used SGLT2i include canagliflozin, dapagliflozin, and empagliflozin [13]. The cardioprotective effects of...